All Stories

  1. Clinical History and Burden of Gaucher Disease Type 3: A Cross‐Sectional Multinational Study
  2. Genetic Testing in Movement Disorders: Riding the Wave Without Being Swept Under
  3. Reply to: “Rare‐Variant Burden in Mitochondrial Parkinson's Disease”
  4. Reply to: Complementary Mitochondrial and α‐Synuclein Signatures Refine Biological Stratification of Parkinson's Disease
  5. Age-Specific Parkinson Disease Risk in Gaucher Disease Type 1
  6. Rethinking Mitochondrial Parkinson's Disease in the α‐Synuclein Seed Amplification Assays Era
  7. CACNA1C ‐Related Channelopathy Presenting With Adult‐Onset Combined Dystonia‐Parkinsonism: A Novel Neurological Presentation
  8. Metabolomics of Multiple System Atrophy Patient-Derived Striatal Medium Spiny Neurons
  9. Sex-Independent Upregulation of miR-146a-5p in Parkinson’s Disease Patients: A Longitudinal Study
  10. The Emotional Landscape of Multiple System Atrophy: A Preliminary Personality-Based Perspective
  11. Artificial Intelligence Predicts GBA1 Mutated Status in Parkinson's Disease Patients
  12. Proteomics of Patient-Derived Striatal Medium Spiny Neurons in Multiple System Atrophy
  13. A Twisting Diagnosis: A New Case of VPS16‐Related Hyperkinetic Spectrum and Literature Review
  14. Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study
  15. RAB32-linked Parkinson’s disease: Deep phenotyping, MDSGene literature review, and application of SynNeurGe criteria
  16. Disease-modifying therapy in GBA1-related Parkinson's disease: the type of variant matters
  17. Gender Is the Main Predictor of Wearing‐Off and Dyskinesia in Levodopa‐Naïve Patients with Parkinson's Disease
  18. LONG-NEXT: A new accurate and efficient NGS-based method for GBA1 analysis in Parkinson disease
  19. 18F-FDG PET findings in Parkinson's disease associated to RAB32 S71R variant
  20. Reply: “Enhancing Parkinson's Disease Research: Recommendations for Addressing Genetic and Environmental Influences in Family History Studies”
  21. The Genetic Epidemiology of Parkinson's Disease view
  22. Adult‐Onset Dystonia‐Parkinsonism: Do Not Forget SERAC1
  23. Coenzyme Q10 deficiency disrupts lipid metabolism by altering cholesterol homeostasis in neurons
  24. A De Novo SCN2A Variant in a Patient with Adult‐Onset Dystonia Parkinsonism and Nigrostriatal Denervation
  25. Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia
  26. Oxidative Stress: A New Pathophysiological Pathway in Parkinson’s Disease and a Potential Target of the Brain‐Sport Crosstalk
  27. Distinctive cognitive phenotypes in Parkinson’s disease patients with GBA mutations and without dementia: a multicentre cross-sectional retrospective study
  28. Long-term motor and cognitive outcome of Deep Brain Stimulation in GBA-PD: the Italian PARKNET study
  29. Childhood-onset focal epilepsy and acute para-infectious encephalopathy in a patient with biallelic QARS1 variants
  30. Lewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids
  31. RAB32 mutation in Parkinson's disease
  32. RAB32 mutation in Parkinson's disease
  33. Dystonic Tremor as Main Clinical Manifestation of SCA21
  34. Obsessive-compulsive disorder as a first manifestation of Ataxia with Oculomotor Apraxia type 2 due to a novel mutation of SETX gene
  35. Neurosteroid Levels in GBA Mutated and Non-Mutated Parkinson’s Disease: A Possible Factor Influencing Clinical Phenotype?
  36. Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?
  37. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease
  38. The p.Val234Met LRP10 likely pathogenic variant associated with Parkinson's disease: Possible molecular implications
  39. Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson’s Disease: A Retrospective Study by Different Expert Centers
  40. Soft cerebellar signs unveil RARS2‐related epilepsy
  41. A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With Dystonia-Parkinsonism
  42. Unleashing the potential of mRNA therapeutics for inherited neurological diseases
  43. Comparing Essential Tremor with and without Soft Dystonic Signs and Tremor Combined with Dystonia: The TITAN Study
  44. Genotype–phenotype correlation in PRKN-associated Parkinson’s disease
  45. A Novel Pathogenic PSEN1 Variant in a Patient With Dystonia-Parkinsonism Without Dementia
  46. Genetics in Parkinson’s disease, state-of-the-art and future perspectives
  47. Response to: Are there two disjunct episignatures for KMT2B-related disease?
  48. Investigating the prevalence of MFN2 mutations in amyotrophic lateral sclerosis: insights from an Italian cohort
  49. Dominant VPS16 Pathogenic Variants: Not Only Isolated Dystonia
  50. Are patients with GBA–Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort
  51. Speech, Gait, and Vestibular Function in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome
  52. Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study
  53. Editorial: Genetic advances and translational applications in movement disorders
  54. Clinical correlates of “pure” essential tremor: the TITAN study
  55. GABRB1‐related early onset developmental and epileptic encephalopathy: Clinical trajectory and novel de novo mutation
  56. Chorea‐Acanthocytosis Presenting with Parkinsonism‐Dystonia without Chorea
  57. Levodopa responsive asymmetric parkinsonism as clinical presentation of progranulin gene mutation.
  58. Dystonia Linked to EIF4A2 Haploinsufficiency: A Disorder of Protein Translation Dysfunction
  59. Don’t forget Allgrove syndrome in adult patients as a bulbar-ALS mimicker
  60. The unexpected finding of CNS autoantibodies in GBA1 mutation carriers with atypical parkinsonism
  61. A form of inherited hyperferritinemia associated with bi-allelic pathogenic variants of STAB1
  62. SCARB1 downregulation in adrenal insufficiency with Allgrove syndrome
  63. Kufor Rakeb syndrome without gaze palsy and pyramidal signs due to novel ATP13A2 mutations
  64. Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation
  65. Reply to: “Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort”
  66. Genetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview
  67. Whole-Exome Sequencing Study of Fibroblasts Derived From Patients With Cerebellar Ataxia Referred to Investigate CoQ10 Deficiency
  68. Deconstructing speech alterations in episodic ataxia type 2: Perceptual-acoustic analysis in a case due to CACNA1A gene mutation
  69. Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
  70. Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
  71. iPSC-Derived Striatal Medium Spiny Neurons from Patients with Multiple System Atrophy Show Hypoexcitability and Elevated α-Synuclein Release
  72. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms
  73. Tremulous spastic ataxia in a patient with a homozygous truncating SYNE1 variant
  74. Verbal Learning Impairment in Parkinson’s Disease: Role of the Frontostriatal System in Working and Strategic Memory
  75. Early-onset inherited dystonias versus late-onset idiopathic dystonias: Same or different biological mechanisms?
  76. Two cases of Huntington’s disease unmasked by the COVID-19 pandemic
  77. A sensitive method for determining UDP-glucose: ceramide glucosyltransferase (UGCG) activity in biological samples using deuterated glucosylceramide as acceptor substrate
  78. Anderson–Fabry Disease: A New Piece of the Lysosomal Puzzle in Parkinson Disease?
  79. BiallelicSTAB1pathogenic variants cause hereditary hyperferritinemia
  80. Nuclear Pore Complex Dysfunction in Dystonia Pathogenesis: Nucleoporins in the Spotlight
  81. Approaching the Gut and Nasal Microbiota in Parkinson’s Disease in the Era of the Seed Amplification Assays
  82. SCARB1 downregulation in adrenal insufficiency with Allgrove Syndrome
  83. Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts
  84. Adult-onset KMT2B-related dystonia
  85. A Bayesian approach to Essential Tremor plus: A preliminary analysis of the TITAN cohort
  86. Juvenile-onset dystonia with spasticity in Leigh syndrome caused by a novel NDUFA10 variant
  87. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease
  88. Trial of Cinpanemab in Early Parkinson’s Disease
  89. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration
  90. Changes in non-motor symptoms in patients with Parkinson's disease following COVID-19 pandemic restrictions: A systematic review
  91. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease
  92. Case Report: Effect of Targeted Therapy With Carbamazepine in KCNQ2 Neonatal Epilepsy
  93. TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study
  94. The apparent paradox of phenotypic diversity and shared mechanisms across dystonia syndromes
  95. Axial improvement after casirivimab/imdevimab treatment for COVID-19 in Parkinson Disease
  96. Correction to: The Italian tremor Network (TITAN): rationale, design and preliminary findings
  97. Cognitive and Autonomic Dysfunction in Multiple System Atrophy Type P and C: A Comparative Study
  98. Genetic evaluation in phenotypically discordant monozygotic twins with Coats Disease
  99. The Italian tremor Network (TITAN): rationale, design and preliminary findings
  100. Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review
  101. Progressive myoclonus without epilepsy due to a NUS1 frameshift insertion: Dyssynergia cerebellaris myoclonica revisited
  102. Dysautonomia in Parkinson’s Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control
  103. Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia
  104. Role of Lysosomal Gene Variants in Modulating GBA ‐Associated Parkinson's Disease Risk
  105. A Practical Approach to Early-Onset Parkinsonism
  106. Freezing of gait: overview on etiology, treatment, and future directions
  107. VPS13C-associated Parkinson's disease: Two novel cases and review of the literature
  108. Transcriptome deregulation of peripheral monocytes in GBA-related Parkinson’s disease
  109. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
  110. Parkinsonism and ataxia
  111. The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson’s disease
  112. A 79-year-old man with unexplained recurrent syncope and severe orthostatic hypotension
  113. Sodium Levels Predict Disability at Discharge in Guillain-Barré Syndrome: A Retrospective Cohort Study
  114. Screening of LRP10 mutations in Parkinson's disease patients from Italy
  115. Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia
  116. HOPS-associated neurological disorders (HOPSANDs): linking endolysosomal dysfunction to the pathogenesis of dystonia
  117. Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis
  118. Targeting the Autonomic Nervous System for Risk Stratification, Outcome Prediction and Neuromodulation in Ischemic Stroke
  119. Clinical features and disease course of patients with acute ischaemic stroke just before the Italian index case: Was COVID-19 already there?
  120. A novel homozygous VPS11 variant may cause generalized dystonia
  121. Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review
  122. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  123. Expanding the genotypic and phenotypic spectrum of Beta‐propeller potein‐associated neurodegeneration
  124. A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation
  125. A rapid and low-cost test for screening the most common Parkinson's disease-related GBA variants
  126. Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity
  127. The SPID-GBA study
  128. Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum
  129. Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
  130. Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies
  131. GBA ‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort
  132. Late-onset leukoencephalopathy in a patient with recessive EARS2 mutations
  133. Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration
  134. Design and Operation of the Lombardy Parkinson's Disease Network
  135. Pharmacological Antagonism of Kainate Receptor Rescues Dysfunction and Loss of Dopamine Neurons in a Mouse Model of Human Parkin-induced Toxicity 
  136. The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease
  137. Systemic involvement in adult‐onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome) with a novel mutation of SNORD118 gene
  138. SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy
  139. Microscopic Polyangiitis With Selective Involvement of Central and Peripheral Nervous System: A Case Report
  140. Dystonia‐ataxia syndrome with permanent torsional nystagmus caused by ECHS1 deficiency
  141. Childhood onset dystonia with cerebellar signs: expanding the spectrum of GNAL mutations
  142. Loss of the nucleoporin Aladin in central nervous system and fibroblasts of Allgrove Syndrome
  143. Validation of the Italian version of the PSP Quality of Life questionnaire
  144. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives
  145. Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy
  146. Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy
  147. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
  148. Parkinsonism in diseases predominantly presenting with dystonia
  149. Spinal direct current stimulation (tsDCS) in hereditary spastic paraplegias (HSP): A sham-controlled crossover study
  150. Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy
  151. Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy
  152. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study
  153. Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?
  154. Syncope and autonomic failure in a middle-aged man
  155. The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson’s Disease
  156. Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss
  157. In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells
  158. A de novo C19orf12 heterozygous mutation in a patient with MPAN
  159. Real life evaluation of safinamide effectiveness in Parkinson’s disease
  160. X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene
  161. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p
  162. Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin’s Lymphoma: A Case Report
  163. Mutations in TMEM230 are rare in autosomal dominant Parkinson's disease
  164. Globus pallidus internus deep brain stimulation in PINK-1 related Parkinson's disease: A case report
  165. Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients
  166. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease
  167. Mutational analysis of COQ2 in patients with MSA in Italy
  168. Autophagy in motor neuron disease: Key pathogenetic mechanisms and therapeutic targets
  169. Abnormal brain temperature in early-onset Parkinson's disease
  170. Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson’s Disease
  171. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation
  172. Designing geographical indication institutions when stakeholders’ incentives are not perfectly aligned
  173. Adaptive deep brain stimulation in patients with Parkinson’s disease: phase II clinical trial preliminary results
  174. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis
  175. Adaptive deep brain stimulation in a freely moving parkinsonian patient
  176. A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism
  177. Cerebellar tDCS: How to Do It
  178. Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation
  179. Biochemical markers in early diagnosis and management of systemic amyloidoses
  180. Obesity and Headache/Migraine: The Importance of Weight Reduction through Lifestyle Modifications
  181. Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism
  182. Mutations in DNA2 Link Progressive Myopathy to Mitochondrial DNA Instability
  183. Congenital Myasthenic Syndrome Due to Choline Acetyltransferase Mutations in Infants
  184. The novel mitochondrial tRNAAsn gene mutation m.5709T>C produces ophthalmoparesis and respiratory impairment
  185. Two novel mutations in PEO1 (Twinkle) gene associated with chronic external ophthalmoplegia
  186. Unusual adult-onset Leigh syndrome presentation due to the mitochondrial m.9176T>C mutation
  187. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
  188. Autosomal dominant restless legs syndrome maps to chromosome 20p13 (RLS-5) in a Dutch kindred
  189. GIGYF2 mutations are not a frequent cause of familial Parkinson's disease
  190. The Mitochondrial Disulfide Relay System Protein GFER Is Mutated in Autosomal-Recessive Myopathy with Cataract and Combined Respiratory-Chain Deficiency
  191. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome
  192. Pseudo-orthostatic and resting leg tremor in a large spanish family with homozygous truncating parkin mutation
  193. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population
  194. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
  195. LRRK2 MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8
  196. SPG11: a consistent clinical phenotype in a family with homozygous Spatacsin truncating mutation
  197. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
  198. Parkin polymorphisms and environmental exposure: Decrease in age at onset of Parkinson's disease
  199. LRRK2 mutations and Parkinson's disease in Sardinia—A Mediterranean genetic isolate
  200. High prevalence ofLRRK2 mutations in familial and sporadic Parkinson's disease in Portugal
  201. Neuropathology of Parkinson's disease associated with theLRRK2 Ile1371Val mutation
  202. 1.283 Clinical and genetic study of a large Dutch family with autosomal dominant restless legs syndrome
  203. 2.119 Parkin polymorphisms and environmental exposure: Reduction of Parkinson's disease age of onset
  204. LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample
  205. The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence
  206. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan
  207. Striatal dopamine transporter binding in Parkinson's disease associated with theLRRK2 Gly2019Ser mutation
  208. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
  209. A case of CPT deficiency, homoplasmic mtDNA mutation and ragged red fibers at muscle biopsy
  210. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease
  211. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor
  212. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease
  213. POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions
  214. Remarkable infidelity of polymerase  A associated with mutations in POLG1 exonuclease domain
  215. Novel missense mutation and large deletion ofGNE gene in autosomal-recessive inclusion-body myopathy